NCT03995134View on ClinicalTrials.gov

Target Controlled Infusion Using Propofol and Remifentanil for Moderate Sedation in Dentistry

CompletedOBSERVATIONAL
Enrollment

101

Participants

Timeline

Start Date

August 3, 2019

Primary Completion Date

January 17, 2020

Study Completion Date

January 17, 2020

Conditions
Sedative Adverse Reaction
Interventions
COMBINATION_PRODUCT

Propofol and Remifentanil administered by TCI pump

Propofol, Remifentanil, Alaris PK (pharmacokinetic) infusion pump with TCI

Trial Locations (2)

T5N 4A3

Dr. Douglas Lobb, Edmonton

Unknown

Dr. Don Macalister, Auckland

All Listed Sponsors
lead

University of Alberta

OTHER

NCT03995134 - Target Controlled Infusion Using Propofol and Remifentanil for Moderate Sedation in Dentistry | Biotech Hunter | Biotech Hunter